
FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003	0280617

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: NABIL HANNA et al.

Appln. No.: 09/853,581

Filing Date: May 14, 2001

Date: September 24, 2004 Page 1 of 1

Examiner: Gary B. Nickol | Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,585,103	12/17/96	Raychaudhuri, et. al. (claims only)			7/24/92
	BR	5,695,770	12/9/97	Raychaudhuri, et al. (claims only)			6/7/95
	CR	5,709,860	1/20/98	Raychaudhuri, et al. (claims only)			12/7/94
	DR	6,197,311	3/6/01	Raychaudhuri, et al. (claims only)			2/17/98
	ER						
	FR						
	GR						
	HR						
	IR						
	JR						
	KR						
	LR						
	MR						
	NR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
	OR									
	PR									
	QR									
	RR									
	SR									
	TR									
	UR									
	VR									
	WR									
	XR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	YR	Francis R. Carbone and Michael J. Bevan, "Class I-Restricted Processing and Presentation of Exogenous Cell-Associated with Antigen In Vivo," February 1990, 171:377-387.
	ZR	Hidemi Takahashi, Toshiyuki Takeshita, Bror Morein, Scott Putney, Ronald N. Germain and Jay A. Berzofsky, "Induction of $CD8^+$ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs" *Nature,* April 26, 1990, 344:873-875
	AAF	Mark W. Moore, Francis R. Carbone, and Michael J. Bevan, "Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation" *Cell*, September 9, 1988, 54:777-785

	BBR	Brown et al., Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol. 2004 Jun;125(6):743-8.				
	CCR	Comerci et al., Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer. 1996 Mar 15;77(6):1107-14.				
	DDR	De Wever et al., Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-{beta} or wounding. J Cell Sci. 2004 Oct 15;117(Pt 20):4691-4703. Epub 2004 Aug 25.				
	EER	Hasegawa et al., Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001 Mar 1;91(5):964-71.				
	FFR	Lee et al., Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int J Cancer. 2001 Nov15;94(4):500-7.				
	GGR	Matsunaga et al., Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. Ann Hematol. 2004 May;83(5):322-5. Epub 2003 Nov 11.				
	HHR	Medrano et al., Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene. 2003 May 19;22(20):3123-9.				
	IIR	Mitani, Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. 2004 May 24;23(24):4263-9.				
	JJR	Mitropoulos et al., Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res. 2004 Sep 7 [Epub ahead of print]				
	KKR	Matar et al., Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol. 2001 Feb;1(2):307-19.				
	LLR	Piestrzeniewicz-Ulanska et al., Expression and intracellular localization of Smad proteins in human endometrial cancer. Oncol Rep. 2003 Sep-Oct;10(5):1539-44.				
	MM	Sacco et al., Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine. 2000 Jun;12(6):811-4.				
	NNR	Schiemann et al. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev. 2004;28(1):57-64.				
	OOR	Seoane et al., Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004 Apr 16;117(2):211-23.				
	PPR	Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 1;19(11):2856-64.				
	QQR	Shariat et al., Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15;92(12):2985-92.				
	RRR	Sheen-Chen et al., Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. 2001 Aug;136(8):937-40.				

	SSR	Subramanian et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 2004 Aug 1;64(15):5200-11.				
	TTR	Lian et al., Enhanced expression of transforming growth factor-beta isoforms in the neural tube of embryos derived from diabetic mice exposed to cyclophosphamide. Neurosci Lett. 2003 Nov 6;351(1):51-5.				
	UUR	Weiner et al., Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002 Apr;8(2):142-54.				
	VVR	Xu et al., Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer. 1999 Aug 20;84(4):396-9.				
	WWR	Xi et al., Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technolog Med Sci. 2004;24(1):62-5.				
	XXR	Xiong et al., Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J Gastroenterol. 2002 Aug;8(4):674-8.				
	YYR	Takiguchi et al., Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor. Anticancer Res. 2004, 24(3a):1823-8.				

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.